Early response to guselkumab and biologic-naïve status predict sustained efficacy with extended dosing intervals in mild-to-moderate plaque psoriasis: A real-world retrospective study

Published: 9 March 2026| Version 1 | DOI: 10.17632/brrvkg7vss.1
Contributors:
,
,

Description

These are the supplementary materials associated with the manuscript submitted to the Journal of the American Academy of Dermatology entitled “Early response to guselkumab and biologic-naïve status predict sustained efficacy with extended dosing intervals in mild-to-moderate plaque psoriasis: A real-world retrospective study”. The files include supplementary methods describing the treatment protocol, study population, and statistical analysis, a supplementary table reporting the multivariable generalized linear mixed model analysis of predictors of long-term treatment success, and a supplementary figure illustrating the study design and treatment assessment timeline. These materials provide additional methodological details and supporting analyses referenced in the main manuscript.

Files

Categories

Dermatology, Biologic Therapy, Clinical Analysis, Psoriasis, Dosing Studies

Licence